---

Most Common Pediatric Diseases in Pakistan's Hospitals

Note: Pakistan does not maintain a fully unified national pediatric disease registry. The data below is synthesized from the largest available hospital-based studies, including a tertiary-care ED study in Karachi covering 188,303 children in one year (Ochsner Journal, 2019), a prospective cohort from Sanghar district hospital (PMC, 2024), and WHO/IHME burden-of-disease data for Pakistan.

---

🔴 Tier 1 — Highest Burden (Most Frequent Hospital Presentations)

---

🟠 Tier 2 — Very Common (Major Admission Diagnoses)

---

🟡 Tier 3 — Significant but Less Frequent

---

🟢 Tier 4 — Notable / Emerging Concerns

---

Age-Group Breakdown

---

Key Underlying Drivers in Pakistan

• Poor sanitation & contaminated water → diarrhea, typhoid, hepatitis A/E
• Low vaccination coverage (~60%) → measles, polio, pertussis
• Malnutrition → amplifies severity of every infectious disease
• Consanguinity (~60% in Pakistan) → genetic diseases (thalassaemia, CHD, inborn errors)
• Unsafe injection practices → iatrogenic HIV, hepatitis B/C
• Inadequate neonatal care → high neonatal mortality (69.3/1,000 live births)

---

---

🫁 PART 1: PNEUMONIA

---

1. Pathophysiology — USMLE Core Concepts

Mechanism of Consolidation (4 Classic Stages of Lobar Pneumonia):

USMLE High-Yield: Grey hepatization → WBCs replace RBCs. Failure to resolve → organizing pneumonia or lung abscess.

Why Do Patients Desaturate?

• Alveoli are filled → V/Q mismatch (perfused but not ventilated = intrapulmonary shunt)
• This causes hypoxemia that does NOT correct well with supplemental O₂ (hallmark of shunt physiology)

Inflammatory Cascade:

• Bacteria (e.g., S. pneumoniae) activate complement → C3a/C5a → neutrophil recruitment → cytokine storm (IL-1, IL-6, TNF-α) → fever, consolidation, systemic illness

---

2. Etiology by Age Group (USMLE-Tested Pattern)

USMLE Mnemonics:

• Atypical organisms = Mycoplasma, Chlamydia, Legionella → Macrolide (azithromycin) coverage
• Klebsiella = alcoholic + currant-jelly sputum + upper lobe cavitary
• Legionella = AC units/water cooling towers + hyponatremia + diarrhea → Legionella urinary antigen test

---

3. Clinical Presentation

Typical (Bacterial — S. pneumoniae):

• Sudden onset high fever, rigors, pleuritic chest pain
• Productive rust-colored sputum
• Lobar consolidation on CXR
• Exam: ↓ breath sounds, dullness to percussion, egophony, bronchial breathing

Atypical (Mycoplasma, Chlamydia, Viral):

• Gradual onset, low-grade fever
• Dry, non-productive cough
• "Worse on X-ray than clinically" (bilateral interstitial infiltrates, patient walks in looking well)
• Extrapulmonary features: bullous myringitis (Mycoplasma), pharyngitis, rash

Pediatric Red Flags:

• Tachypnea disproportionate to fever = earliest sign in children
• Intercostal/subcostal retractions
• Nasal flaring, grunting (infants)
• WHO criteria: RR >50/min (2–12 months), >40/min (1–5 years) = pneumonia

---

4. Diagnosis

---

5. Treatment & Management

Outpatient (CAP, mild):

Inpatient (Moderate-Severe CAP):

• β-lactam + Macrolide (e.g., Ceftriaxone + Azithromycin) OR
• Respiratory fluoroquinolone (Levofloxacin monotherapy)

ICU / Severe CAP:

• Ceftriaxone + Azithromycin + Vancomycin (if MRSA suspected: post-influenza, necrotic cavities)

Supportive:

• Supplemental O₂ → target SpO₂ ≥94%
• IV fluids if dehydrated
• Antipyretics (Paracetamol/Ibuprofen — avoid aspirin in children → Reye syndrome)
• Severity scores: CURB-65 (adults), PSI; for children → WHO criteria guides step-up

Prevention:

• PCV13/PCV15 (pneumococcal conjugate) — routine childhood immunization
• Influenza vaccine — annually (reduces secondary bacterial pneumonia)

---

---

🔴 PART 2: MEASLES (RUBEOLA)

---

1. Pathophysiology — USMLE Core Concepts

The Virus:

• Paramyxovirus, genus Morbillivirus
• Single-stranded, negative-sense RNA virus
• R₀ = 12–18 (most contagious human pathogen known)
• Transmission: respiratory droplets + airborne (viable in air for up to 2 hours)
• Single serotype → one strain of vaccine protects against all 24 genotypes

Step-by-Step Pathogenesis:

Inhalation of virus
       ↓
Infects respiratory epithelium via CD150 (SLAM) receptor & Nectin-4
       ↓
Replication in local lymph nodes → PRIMARY VIREMIA (Day 1–2)
       ↓
Spreads to RES (liver, spleen, lymph nodes, bone marrow)
→ SECONDARY VIREMIA (Day 5–7)
       ↓
Dissemination to skin, conjunctiva, respiratory tract, GI tract
       ↓
Cell-mediated immune response → characteristic RASH (Day 14)
       ↓
Immunosuppression ("immune amnesia") persists for months–years

USMLE High-Yield — Immune Amnesia: Measles virus depletes pre-existing antibody-secreting B cells → wipes out immunological memory → children become susceptible to other infections they were previously immune to for 2–3 years after measles. This explains excess mortality in the post-measles period.

Why the Rash Appears When It Does:

• The rash is NOT due to direct viral damage — it is the result of the CD4+ T-cell immune response attacking virus-infected endothelial cells in the skin
• Immunocompromised patients (no cellular immunity) → no rash but very high mortality (giant cell pneumonitis)

---

2. Clinical Presentation — The "3 C's + Rash" Rule

Prodrome (Days 1–4 after symptoms):

Cough + Coryza + Conjunctivitis + High Fever

• Fever can reach 40–41°C (104–106°F) — alarming, prolonged
• Koplik spots appear 1–2 days BEFORE rash → pathognomonic

Koplik spots: 1mm bluish-white papules on erythematous base, on buccal mucosa opposite the lower molars. Fade with rash onset.

Exanthem (Rash — Day 14 after exposure):

• Begins: behind ears → hairline → face
• Spreads: cephalocaudal (head → trunk → extremities) over 3 days
• Character: maculopapular, confluent (unlike rubella which stays discrete)
• Clears in same order it appeared; may desquamate in malnourished children

---

3. Timeline (USMLE Favorite!)

Contagious period: 4 days before to 4 days after rash onset (4+4 rule)

---

4. Complications (Tested Heavily on USMLE)

USMLE High-Yield on SSPE: Periodic complexes on EEG + high measles IgG/IgM in CSF + progressive cognitive decline → diagnosis of SSPE

---

5. Diagnosis

CDC Case Definition: Maculopapular rash ≥3 days + fever ≥38.3°C + at least one of: cough, coryza, or conjunctivitis

---

6. Treatment & Management

There is NO specific antiviral therapy for measles. Treatment is supportive.

Supportive Care:

• Antipyretics (Paracetamol — not aspirin)
• Oral rehydration / IV fluids
• Nutritional support
• Isolation (droplet + airborne precautions; negative pressure room if available)
• Treat secondary bacterial infections (otitis media, pneumonia) with antibiotics

🌟 Vitamin A — THE KEY TREATMENT (High-Yield for USMLE & Pakistan):

Why Vitamin A? Measles → Vitamin A depletion → ↑ morbidity/mortality. Vit A restores epithelial integrity, immune function. WHO recommends for ALL hospitalized children with measles in countries with high deficiency (Pakistan qualifies). Reduces mortality by ~50% in malnourished children.

Neurological Complications:

• No proven therapy for SSPE or measles encephalitis
• Ribavirin, interferon-α, and isoprinosine have limited observational evidence

---

7. Prevention

---

🧠 USMLE One-Liners Summary

---